Holen Sie sich die Stockscreener-App
146.00
1.72%
-2.56
Handel nachbörslich:
145.51
-0.49
-0.34%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$148.56
Offen:
$147.11
24-Stunden-Volumen:
5.55M
Relative Volume:
0.77
Marktkapitalisierung:
$181.25B
Einnahmen:
$29.45B
Nettoeinkommen (Verlust:
$8.51B
KGV:
21.53
EPS:
6.7823
Netto-Cashflow:
$9.46B
1W Leistung:
-1.50%
1M Leistung:
-6.29%
6M Leistung:
+23.88%
1J Leistung:
+27.59%
1-Tages-Spanne:
$145.81
$149.30
1-Wochen-Bereich:
$142.77
$149.38
52-Wochen-Spanne:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
146.00 | 184.43B | 29.45B | 8.51B | 9.46B | 6.7823 |
|
LLY
Lilly Eli Co
|
999.84 | 894.20B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.99 | 587.32B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.68 | 401.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
193.31 | 302.39B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
155.80 | 308.34B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene - StreetInsider
News | British Land and Royal London sign Gilead at Euston development - CoStar
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification - simplywall.st
Gilead Sciences, Inc. $GILD Shares Sold by Mackenzie Financial Corp - MarketBeat
Magnetar Financial LLC Increases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead at Leerink Conference: Strategic Expansion in Healthcare - Investing.com India
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained - AOL.com
Jefferies Initiates Coverage on Gilead Sciences (GILD) with 'Buy' Rating | GILD Stock News - GuruFocus
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained - 24/7 Wall St.
What 16 Analyst Ratings Have To Say About Gilead Sciences - Benzinga
Gilead Sciences (NASDAQ:GILD) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Gilead price boosted by important supportForecast today10-03-2026 - Economies.com
Gilead Sciences, Inc. $GILD Shares Sold by Richard Bernstein Advisors LLC - MarketBeat
Gilead Sciences, Inc. $GILD Stock Position Decreased by Capital Research Global Investors - MarketBeat
Gilead Sciences, Inc. $GILD Holdings Trimmed by Capital World Investors - MarketBeat
Capital International Inc. CA Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Jefferies initiates Gilead Sciences stock with buy rating By Investing.com - Investing.com Canada
Legal & General Group Plc Buys 414,454 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Russell Investments Group Ltd. Sells 49,215 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Fieldview Capital Management LLC Invests $1.91 Million in Gilead Sciences, Inc. $GILD - MarketBeat
GILEAD SCIENCES INC (NASDAQ:GILD): A Durable Dividend Stock for Income Investors - ChartMill
Jefferies initiates Gilead Sciences stock with buy rating - Investing.com
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Insider Monkey
Banque Cantonale Vaudoise Has $8.91 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know - Yahoo Finance
How Low Can Gilead Sciences Stock Really Go? - Trefis
Swiss National Bank Has $398 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Schroder Investment Management Group Has $230.08 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by WINTON GROUP Ltd - MarketBeat
Vinva Investment Management Ltd Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Kiltearn Partners LLP - MarketBeat
Natixis Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
B. Metzler seel. Sohn & Co. AG Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Citigroup Maintains Buy on GILD (Gilead Sciences, Inc.) March 2026 - Meyka
Arcellx set to report earnings amid $7.8B Gilead deal - Investing.com
United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Has $2.81 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Parallel Advisors LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Korea Investment CORP Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Rhenman & Partners Asset Management AB Sells 88,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Blair William & Co. IL - MarketBeat
Is It Time To Reassess Gilead Sciences (GILD) After Its Strong Share Price Run - Yahoo Finance
Gilead’s BIC LEN HIV Results Highlight Valuation Gap And Future Potential - Yahoo Finance
Gilead Sciences, Inc. $GILD Shares Purchased by HUB Investment Partners LLC - MarketBeat
Munich Reinsurance Co Stock Corp in Munich Takes $67.50 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
First Trust Advisors LP Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
GILD Stock Quote Price and Forecast - CNN
Is Gilead Sciences Inc. stock overvalued by current metricsWeekly Trade Review & Low Drawdown Momentum Trade Ideas - Naître et grandir
These 3 Cash Flow Machines Provide Stability in Uncertain Markets - Investing.com
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term - Yahoo Finance
BofA reiterates Gilead Sciences stock Buy rating on Yeztugo uptake - Investing.com
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.28%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):